Search Results - Kim Papp

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patien... by Ahmad Jalili, Henrik Thoning, Marie Y. Jablonski Bernasconi, Kim Papp

Connect to this object online.

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis by Kim Papp, Carle Paul, C. Elise Kleyn, Yu-Huei Huang, Tsen-Fang Tsai, Christopher Schuster, Celine El Baou, Agoston Toth, Elisabeth Riedl, Ulrich Mrowietz

Connect to this object online.

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure by April Armstrong, Carle Paul, Luis Puig, Wolf Henning Boehncke, Michael Freeman, Hideshi Torii, Kim Papp, Christopher E. M. Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, Lisa Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark G. Lebwohl

Connect to this object online.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials by Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp

Connect to this object online.